Similar articles

• The evaluation of a novel corticosteroid formulation, fluocinonide in "FAPG" base, in the blanching test.

  Coldman MF, Lockerbie L, Laws EA. Coldman MF, et al. Br J Dermatol. 1971 Dec;85(6):573-6. doi: 10.1111/j.1365-2133.1971.tb14085.x. Br J Dermatol. 1971. PMID: 4947552 Clinical Trial. No abstract available.
• Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.

  Barry BW, Woodford R. Barry BW, et al. Br J Dermatol. 1974 Sep;91(3):323-38. doi: 10.1111/j.1365-2133.1974.tb12903.x. Br J Dermatol. 1974. PMID: 4611447 Clinical Trial. No abstract available.
• [Remarks on the percutaneous absorption of corticoids].

  Rimbaud P, Meynadier J. Rimbaud P, et al. Ann Dermatol Syphiligr (Paris). 1968;95(3):263-7. Ann Dermatol Syphiligr (Paris). 1968. PMID: 5697207 French. No abstract available.
• Recent progress in the formulation of vehicles for topical applications.

  Hadgraft JW. Hadgraft JW. Br J Dermatol. 1972 Oct;87(4):386-9. doi: 10.1111/j.1365-2133.1972.tb07428.x. Br J Dermatol. 1972. PMID: 4562170 Review. No abstract available.
• The absorption of topical corticosteroids, with particular reference to percutaneous absorption in infancy and childhood.

  Keipert JA. Keipert JA. Med J Aust. 1971 May 8;1(19):1021-5. doi: 10.5694/j.1326-5377.1971.tb88011.x. Med J Aust. 1971. PMID: 4930660 Review. No abstract available.